Olopatadine/mometasone
| Combination of | |
|---|---|
H1-receptor antagonist | |
| Mometasone | Corticosteroid |
| Clinical data | |
| Trade names | Ryaltris |
| Other names | GSP 301 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Nasal spray |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Olopatadine/mometasone, sold under the brand name Ryaltris, is a
Common side effects include an unpleasant taste (dysgeusia).[1]
It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2]
References
- ^ a b c d e f g "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
- ^ a b c d e "Ryaltris- olopatadine hydrochloride and mometasone furoate spray, metered". DailyMed. 9 January 2022. Retrieved 20 June 2022.
- S2CID 238223252.
- ^ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.
External links
- "Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
- "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
- Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov
